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Abstract
Background: The protein tyrosine phosphatase N22 gene (PTPN22) encodes a lymphoid-specific
phosphatase (LYP) which is an important downregulator of T cell activation. A PTPN22
polymorphism, C1858T, was found associated with type 1 diabetes (T1D) in different Caucasian
populations. In this study, we aimed at confirming the role of this variant in T1D predisposition in
the Spanish population.
Methods: A case-control was performed with 316 Spanish white T1D patients consecutively
recruited and 554 healthy controls, all of them from the Madrid area. The PTPN22 C1858T SNP
was genotyped in both patients and controls using a TaqMan Assay in a 7900 HT Fast Real-Time
PCR System.
Results: We replicated for the first time in a Spanish population the association of the 1858T allele
with an increased risk for developing T1D [carriers of allele T vs. CC: OR (95%) = 1.73 (1.17–2.54);
p = 0.004]. Furthermore, this allele showed a significant association in female patients with diabetes
onset before age 16 years [carriers of allele T vs. CC: OR (95%) = 2.95 (1.45–6.01), female patients
vs female controls p = 0.0009]. No other association in specific subgroups stratified for gender,
HLA susceptibility or age at onset were observed.
Conclusion: Our results provide evidence that the PTPN22 1858T allele is a T1D susceptibility
factor also in the Spanish population and it might play a different role in susceptibility to T1D
according to gender in early-onset T1D patients.
Background
Type 1 diabetes (T1D) is an autoimmune disorder result-
ing from destruction of the insulin-producing β cells of
the pancreas. T1D is a complex trait with both genetic and
environmental factors contributing to the etiology of this
disease. Several susceptibility loci involved in disease
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development have been identified and were consistently
replicated in independent populations [1]. These efforts
contribute to a better definition of the molecular path-
ways leading to increased T1D risk and this knowledge, in
turn, may help in understanding the genetic basis of the
disease. The MHC class II, the CTLA4 and the PTPN22 loci
have all been proved important in the pathogenesis of
autoimmunity globally considered, whereas the insulin
gene is a disease-specific T1D predisposition locus. Most
of the new general susceptibility loci identified in the past
few years have a clear role in the modulation of T cell
development and activation, indicating that common
biological pathways may be implicated in the etiology of
different autoimmune diseases.
The role of a functional polymorphism of the PTPN22
gene, C1858T, in T1D susceptibility is well established.
Bottini et al were the first to show that the minor allele of
this variant confers predisposition to T1D using a case-
control study with European American and Sardinian
cohorts [2]. The allelic variation of the PTPN22  gene,
1858T, has been found associated with several autoim-
mune disorders: rheumatoid arthritis [3-7], systemic
lupus erythematosus [4], Wegener's granulomatosis [8]
and myasthenia gravis [9] among them, but no associa-
tion was found with either multiple sclerosis [10] or celiac
disease [11]. Confirmation of the PTPN22  association
with T1D was performed in several independent popula-
tions [12-19]. Recently, a study described for the first time
the sex-specific association of this polymorphism with
T1D in Germany [20]. Gender-dependent association of
PTPN22 has been described with rheumatoid arthritis[21]
and with psoriatic arthritis[22], showing a predominant
effect in male in both cases. The purpose of the present
study was to verify the sex-biased association, as it might
underlie a gender-dependent mechanism involved in dis-
ease pathogenesis.
Methods
Patients and controls
We studied 316 white unrelated Spanish T1D patients
(159 women and 157 men) diagnosed according to the
criteria of the American Diabetes Association (ADA) and
554 healthy controls recruited among blood donors from
the Madrid area (therefore with an age ranging from 18–
60 years). The gender distribution in our control group
was: 51% females and 49% males; in 168 anonymous
blood donors gender could not be ascertained.
The age at onset for the consecutively recruited T1D
patients range from 1 to 55 years old (mean: 17.3 ± 10.0
and median age at onset: 15 years). All subjects were insu-
lin-dependent at the time of the study. Informed consent
was obtained from all the subjects included in the study,
which was approved by the Ethics Committee of the Hos-
pital Clínico San Carlos.
Genotyping
Patients and controls were genotyped for the PTPN22
C1858T SNP (rs2476601) using a TaqMan Assay by
Design in a 7900 HT Fast Real-Time PCR System (Applied
Biosystem Foster City, CA, USA). HLA typing was per-
formed as described by Urcelay et al [23].
Statistical analysis
Differences in allele and genotype frequencies were calcu-
lated by Chi-square, or Fisher's exact test when necessary.
Associations were estimated by the odds ratio (OR) with
95% confidence interval (CI). Statistical analysis used Epi
Info v. 6.02 (CDC Atlanta USA). No deviations from
Hardy-Weinberg equilibrium were observed for geno-
types of this polymorphism in our population.
Results
The case-control study showed that the distribution of the
PTPN22 C1858T alleles in the Spanish population was, as
expected, significantly different between patients and con-
trols (Table 1). The minor allele 1858T confers suscepti-
bility to T1D, as already described in other white
populations. Based on the previously reported sex-specific
association found in Germany [20], we tested for associa-
tion in our cohorts after stratifying according to gender.
No significant difference was detected between female
and male T1D patients (Table 1).
In order to study the effect of age at onset on the distribu-
tion of genotypes of this PTPN22  polymorphism, we
divided our patients in two groups, setting the median age
at onset in our cohort (15 years) as the cut-off value. We
selected median instead of mean age, because it is a better
central statistic for highly skewed distributions, as T1D
age at diagnosis is, and it maximizes the statistical power.
We have age at disease onset data for 281 patients and the
distribution of the 1858T allele was no significantly differ-
ent between both groups: carriers of allele 1858T in
younger patients vs. patients older than 15 years [31/141
vs. 28/140 (OR = 1.13; p = 0.68)].
However, when we considered both age and gender strat-
ifications simultaneously (Table 2), in the pediatric-onset
cohort (younger than 16 years old) the frequency of
PTPN22 1858T allele was significantly increased in dia-
betic females, which is the only group significantly differ-
ent from controls (carriers of 1858T, diabetic vs. healthy
females: OR (95%) = 2.95 (1.45–6.01); p = 0.0009).
The association of the HLA class II loci and T1D has been
long established. The HLA-DRB1*03 and HLA-DRB1*04
alleles are the major contributors to T1D susceptibility.BMC Medical Genetics 2007, 8:54 http://www.biomedcentral.com/1471-2350/8/54
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No significant difference in the PTPN22 1858T allele fre-
quencies was found between carriers and non carriers of
those alleles in the diabetes cohort (DRB1*03 and/or
DRB1*04 patients, carriers (61/287) vs. non-carriers (3/
29), OR = 2.34; p = 0.16). It has been reported that HLA
DR3/DR4 genotype confers the strongest genetic risk for
T1D, however, in our Spanish cohort the highest risk gen-
otype for T1D is DRB1*03/DRB1*03 (RR = 22.19 vs. RR =
15.11 for DRB1*03/DRB1*03 and DRB1*03/DRB1*04,
respectively; considering RR = 1 subjects negatives for
these alleles). Therefore, we repeated the analysis of the
PTPN22 polymorphism in our population stratified by
the two abovementioned genotypes and in subjects with-
out both genotypes. The distribution of 1858T allele was
similar in any of the three groups of patients carrying
these genotypes: 10/96 (10.4%) in DRB1*03/DRB1*03
patients, 22/180 (12.2%) in heterozygous DRB1*03/
DRB1*04 and 37/319 (10.4%) in the rest of patients.
Discussion
In agreement with recent findings, our data showed an
association of the PTPN22 1858T allele with T1D in the
Spanish population (Table 1). Despite the fact that T1D is
an autoimmune disease which does not show sex-bias
(gender distribution in our Spanish diabetic population:
50.3% women vs. 49.7% men), Kahles et al [20] reported
an association of PTPN22 1858T allele only in German
T1D females. However, we cannot conclude that this sus-
ceptibility factor is exclusively associated with female
patients, as it has been proposed, because we could not
find a significant difference between diabetic female and
male patients (Table 1). This result agrees with several
studies which do not show a gender-specific effect
[12,14,17,18,24]. The female association found by Kahles
et al [20] and the male association reported by Herman et
al [25] could be due to spurious effects; however, the anal-
ysis in our pediatric-onset patients supports a preferential
association in T1D females (Table 2). This age- and gen-
der-dependent association could explain previous results,
given that the sex-bias is evidenced only in early-onset
patients, but the observed association warrants replication
in independent populations. Recent studies have revealed
that LYP increases phosphatase activity when allele 1858T
is present [26]. This gain of function mutant hypotheti-
cally suppresses T cell signaling more efficiently and leads
to a failure in apoptosis of autoreactive T cells and to an
insufficient activity of regulatory T cells [27]. Given than
women have higher absolute numbers of CD4 lym-
phocytes than men and higher levels of Th1 cytokines
[28], this would justify that the observed role of the
Table 2: Gender and age distribution of the PTPN22 C1858T polymorphism in Spanish T1D patients
Genotypes (%) T1D vs. Controls (carrier of T vs CC)
Subjects CC CT TT OR CI (95%) p
Female T1D ≤ 15 (n = 70) 49 (70.0) 19 (27.1) 2 (2.9) 2.92 (1.59–5.33) 0.0001
Male T1D ≤ 15 (n = 71) 61 (85.9) 10 (14.1) 0 1.12 (0.51–2.37) 0.76
Female T1D > 15 (n = 70) 56 (80.0) 12 (17.1) 2 (2.9) 1.70 (0.85–3.34) 0.10
Male T1D > 15 (n = 70) 56 (80.0) 13 (18.6) 1 (1.4) 1.70 (0.85–3.34) 0.10
Controls 483 (87.2) 68 (12.3) 3 (0.5)
Female T1D ≤ 15 vs. Male T1D ≤ 15:
(TT+CT) vs. CC; OR (95%) = 2.61 (1.05–6.62); p = 0.022
Table 1: Analysis of the PTPN22 C1858T variant in the Spanish cohort
Genotypes (%) Alleles (%)
Subjects CC CT TT C T
Controls (n = 554) 483 (87.2) 68 (12.3) 3 (0.5) 1034 (93.3) 74 (6.7)
Female (n = 197) 172 (87.3) 23 (11.7) 2 (1.0) 367 (93.1) 27 (6.9)
Male (n = 189) 168 (89.9) 20 (10.6) 1 (0.5) 356 (94.2) 22 (5.8)
Cases (n = 316) 252 (79.7) 59 (18.7) 5 (1.6) 563 (89.1) 69 (10.9)
Female (n = 159) 122 (76.7) 33 (20.8) 4 (2.5) 277 (87.1) 41 (12.9)
Male (n = 157) 130 (82.8) 26 (16.1) 1 (0.6) 286 (91.1) 28 (8.9)
Patients vs. controls:
T vs. C; OR (95%) = 1.71 (1.20–2.45); p = 0.002
(TT+CT) vs. CC; OR (95%) = 1.73 (1.17–2.54); p = 0.004BMC Medical Genetics 2007, 8:54 http://www.biomedcentral.com/1471-2350/8/54
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PTPN22 polymorphism is mainly evidenced in girls. Fur-
thermore, in the group with disease onset after 15 years
old no gender differences could be established and both
female and male patients compared with controls showed
OR values of 1.70 (Table 2). In summary, the reasons for
sex differences in early onset in T1D is a complex process
which remains unclear and could mean that there is an
interacting factor with PTPN22 yet to be identified, the
effect of sex hormones or epigenetic modifications of
DNA could explain this gender-dependent association.
In a recent study, Steck et al [24] described a significant
association after stratification by HLA-DRB1 genotypes
only in the non-DRB1*03/04 subgroup. However, as they
recognize, the lack of association in the high-risk HLA-
DRB1 genotype was probably due to compromised statis-
tical power. Moreover, their linear regression analyses did
not reveal interaction between PTPN22 genotypes and the
aforementioned HLA genotype; therefore, they suggest
that PTPN22 influences T1D risk in all HLA subgroups.
The stratification by HLA-DRB1 alleles in our cohort
showed no different frequency of the PTPN22  1858T
allele in any of the patient subgroups. These data suggest
that the susceptibility conferred by the PTPN22 gene is an
independent factor of the HLA effect and patients carrying
the PTPN22 1858T allele have an increased risk for T1D
development independent of this important genetic factor
implicated in the disease.
The proposed PTPN22 model that allows for more autore-
active T cells to survive and escape into circulation could
also determine an earlier age at disease onset; however, no
differences were found between patients younger and
older than 15 years old.
Conclusion
In conclusion, we described for the first time in a Spanish
population the association of the PTPN22 variant with
T1D risk. It seems to be a susceptibility factor for both
male and female T1D patients, although in pediatric-
onset patients the effect seems to be predominant in dia-
betic females. The age at onset in our cohort is similar in
subjects carrying PTPN22  1858T allele and in CC
homozygous individuals and the susceptibility effect of
this variant is independent from the susceptibility con-
ferred by the main HLA-DRB1 alleles associated with T1D.
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